Optimized Infectivity of the Cell-Free Single-Cycle Human Immunodeficiency Viruses Type 1 (HIV-1) and Its Restriction by Host Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Kim, Jin H ^a   Song, Hanna ^a   Austin, Jamie L ^a   Cheng, Wei ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL FREE SYSTEM; CONTROLLED STUDY; CULTURE MEDIUM; GENETIC TRANSFECTION; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PLASMID; TIME; VIRION; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS ENVELOPE; VIRUS VIRULENCE; PATHOGENICITY; VIRULENCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL-FREE SYSTEM; HIV-1; HUMANS; PLASMIDS; TRANSFECTION; VIRION; VIRULENCE;

EID: 84879184324     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067170     Document Type: Article

References (64)

1. Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, et al. (1992) Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 189: 695-714.
2. Bourinbaiar AS, (1994) The ratio of defective HIV-1 particles to replication-competent infectious virions. Acta Virol 38: 59-61.
3. Kwon YJ, Hung G, Anderson WF, Peng CA, Yu H, (2003) Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis. J Virol 77: 5712-5720.
4. Rusert P, Fischer M, Joos B, Leemann C, Kuster H, et al. (2004) Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology 326: 113-129.
5. Thomas JA, Ott DE, Gorelick RJ, (2007) Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions. J Virol 81: 4367-4370.
6. Platt EJ, Kozak SL, Durnin JP, Hope TJ, Kabat D, (2010) Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J Virol 84: 3106-3110.
7. Wyatt R, Sodroski J, (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
8. Greene WC, Peterlin BM, (2002) Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med 8: 673-680.
9. Cavrois M, Neidleman J, Greene WC, (2008) The achilles heel of the trojan horse model of HIV-1 trans-infection. PLoS Pathog 4: e1000051.
10. Binley J, (2009) Specificities of broadly neutralizing anti-HIV-1 sera. Curr Opin HIV AIDS 4: 364-372.
11. Klein JS, Bjorkman PJ, (2010) Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 6: e1000908.
12. Thali M, (2011) Tetraspanin functions during HIV-1 and influenza virus replication. Biochem Soc Trans 39: 529-531.
13. Blumenthal R, Durell S, Viard M, (2012) HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem 287: 40841-40849.
14. Englund G, Theodore TS, Freed EO, Engelman A, Martin MA, (1995) Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol 69: 3216-3219.
15. Krishnan L, Engelman A, (2012) Retroviral integrase proteins and HIV-1 DNA integration. J Biol Chem 287: 40858-40866.
16. Haim H, Steiner I, Panet A, (2005) Synchronized infection of cell cultures by magnetically controlled virus. J Virol 79: 622-625.
17. Bernier R, Tremblay M, (1995) Homologous interference resulting from the presence of defective particles of human immunodeficiency virus type 1. J Virol 69: 291-300.
18. An W, Telesnitsky A, (2001) Frequency of direct repeat deletion in a human immunodeficiency virus type 1 vector during reverse transcription in human cells. Virology 286: 475-482.
19. Preston BD, Poiesz BJ, Loeb LA, (1988) Fidelity of HIV-1 reverse transcriptase. Science 242: 1168-1171.
20. Roberts JD, Bebenek K, Kunkel TA, (1988) The accuracy of reverse transcriptase from HIV-1. Science 242: 1171-1173.
21. Chiu YL, Greene WC, (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 26: 317-353.
22. Harris RS, Hultquist JF, Evans DT, (2012) The restriction factors of human immunodeficiency virus. J Biol Chem 287: 40875-40883.
23. Munk C, Landau NR, (2003) Production and Use of HIV-1 Luciferase Reporter Viruses. Curr Protoc Pharmacol Chapter 12: Unit12.15.
24. Richards KH, Clapham PR (2006) Human immunodeficiency viruses: propagation, quantification, and storage. Curr Protoc Microbiol Chapter 15: Unit15J 11.
25. Montefiori DC (2004) Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays. Curr Protoc Immunol Chapter 12: Units 12.11.
26. McMahon MA, Shen L, Siliciano RF, (2009) New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr Opin Infect Dis 22: 574-582.
27. Yuste E, Reeves JD, Doms RW, Desrosiers RC, (2004) Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol 78: 6775-6785.
28. Poon B, Hsu JF, Gudeman V, Chen IS, Grovit-Ferbas K, (2005) Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses. J Virol 79: 10210-10217.
29. Berkhout B, Haasnoot J, (2006) The interplay between virus infection and the cellular RNA interference machinery. FEBS Lett 580: 2896-2902.
30. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921-926.
31. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
32. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367.
33. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
34. Takeuchi Y, McClure MO, Pizzato M, (2008) Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 82: 12585-12588.
35. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC, (2009) Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 83: 8289-8292.
36. Kimpton J, Emerman M, (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 66: 2232-2239.
37. Wu Y, Marsh JW, (2001) Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 293: 1503-1506.
38. Wiskerchen M, Muesing MA, (1995) Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 69: 376-386.
39. Padow M, Lai L, Deivanayagam C, DeLucas LJ, Weiss RB, et al. (2003) Replication of chimeric human immunodeficiency virus type 1 (HIV-1) containing HIV-2 integrase (IN): naturally selected mutations in IN augment DNA synthesis. J Virol 77: 11050-11059.
40. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, et al. (1995) The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 69: 6304-6313.
41. He J, Choe S, Walker R, Di Marzio P, Morgan DO, et al. (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69: 6705-6711.
42. Rogel ME, Wu LI, Emerman M, (1995) The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 69: 882-888.
43. Re F, Braaten D, Franke EK, Luban J, (1995) Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol. 69: 6859-6864.
44. Cai L, Friedman N, Xie XS, (2006) Stochastic protein expression in individual cells at the single molecule level. Nature 440: 358-362.
45. Carlson LA, Briggs JA, Glass B, Riches JD, Simon MN, et al. (2008) Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. Cell Host Microbe 4: 592-599.
46. Briggs JA, Krausslich HG, (2011) The molecular architecture of HIV. J Mol Biol 410: 491-500.
47. Chertova E, Bess JW Jr, Crise BJ, Sowder IR, Schaden TM, et al. (2002) Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 76: 5315-5325.
48. Schaeffer E, Geleziunas R, Greene WC, (2001) Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J Virol 75: 2993-3000.
49. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB, (2009) HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137: 433-444.
50. Kingston RE, Chen CA, Okayama H (2001) Calcium phosphate transfection. Curr Protoc Immunol Chapter 10: Unit 10 13.
51. Kingston RE, Chen CA, Rose JK (2003) Calcium phosphate transfection. Curr Protoc Mol Biol Chapter 9: Unit 9 1.
52. Checkley MA, Luttge BG, Freed EO, (2011) HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410: 582-608.
53. Crooks ET, Tong T, Osawa K, Binley JM, (2011) Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 85: 5825-5839.
54. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, et al. (1988) Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53: 55-67.
55. Wu Y, Beddall MH, Marsh JW, (2007) Rev-dependent indicator T cell line. Curr HIV Res 5: 394-402.
56. Jouvenet N, Bieniasz PD, Simon SM, (2008) Imaging the biogenesis of individual HIV-1 virions in live cells. Nature 454: 236-240.
57. Ono A, (2009) HIV-1 Assembly at the Plasma Membrane: Gag Trafficking and Localization. Future Virol 4: 241-257.
58. Konig R, Ashwell G, Hanover JA, (1989) Overexpression and biosynthesis of CD4 in Chinese hamster ovary cells: coamplification using the multiple drug resistance gene. Proc Natl Acad Sci U S A 86: 9188-9192.
59. Wu Y, Beddall MH, Marsh JW, (2007) Rev-dependent lentiviral expression vector. Retrovirology 4: 12.
60. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986) Production of Acquired Immunodeficiency Syndrome-Associated Retrovirus in Human and Nonhuman Cells Transfected with an Infectious Molecular Clone. Journal of Virology 59: 284-291.
61. Connor RI, Chen BK, Choe S, Landau NR, (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206: 935-944.
62. Cavrois M, Neidleman J, Bigos M, Greene WC, (2004) Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. Methods Mol Biol 263: 333-344.
63. Joyner AS, Willis JR, Crowe JE Jr, Aiken C, (2011) Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS Pathog 7: e1002234.
64. Otsu N, (1979) Threshold Selection Method from Gray-Level Histograms. Ieee Transactions on Systems Man and Cybernetics 9: 62-66.